CN112842954A - Anti-inflammatory and soothing composition and application thereof in cosmetics - Google Patents
Anti-inflammatory and soothing composition and application thereof in cosmetics Download PDFInfo
- Publication number
- CN112842954A CN112842954A CN202010207882.4A CN202010207882A CN112842954A CN 112842954 A CN112842954 A CN 112842954A CN 202010207882 A CN202010207882 A CN 202010207882A CN 112842954 A CN112842954 A CN 112842954A
- Authority
- CN
- China
- Prior art keywords
- inflammatory
- portions
- parts
- soothing
- palmitoyl tripeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 60
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 239000002537 cosmetic Substances 0.000 title claims abstract description 29
- 239000000284 extract Substances 0.000 claims abstract description 35
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims abstract description 33
- 241000736199 Paeonia Species 0.000 claims abstract description 18
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 16
- 239000000654 additive Substances 0.000 claims description 11
- 230000000996 additive effect Effects 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 244000236658 Paeonia lactiflora Species 0.000 claims description 7
- 235000008598 Paeonia lactiflora Nutrition 0.000 claims description 7
- 239000006210 lotion Substances 0.000 claims description 3
- 239000004909 Moisturizer Substances 0.000 claims description 2
- 239000000853 adhesive Substances 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 230000001815 facial effect Effects 0.000 claims description 2
- 230000001333 moisturizer Effects 0.000 claims description 2
- 239000000049 pigment Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 230000000475 sunscreen effect Effects 0.000 claims description 2
- 239000000516 sunscreening agent Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims 1
- 239000003205 fragrance Substances 0.000 claims 1
- 239000003921 oil Substances 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 13
- 102000004125 Interleukin-1alpha Human genes 0.000 abstract description 10
- 108010082786 Interleukin-1alpha Proteins 0.000 abstract description 10
- 206010061218 Inflammation Diseases 0.000 abstract description 5
- 230000004054 inflammatory process Effects 0.000 abstract description 5
- 102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 abstract description 4
- 102100034216 Melanocyte-stimulating hormone receptor Human genes 0.000 abstract description 4
- 101710161100 Melanocyte-stimulating hormone receptor Proteins 0.000 abstract description 4
- 101710200814 Melanotropin alpha Proteins 0.000 abstract description 4
- 230000000770 proinflammatory effect Effects 0.000 abstract description 4
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 abstract description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 14
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 description 8
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 8
- 229940084032 paeonia lactiflora root extract Drugs 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 230000000172 allergic effect Effects 0.000 description 7
- 208000010668 atopic eczema Diseases 0.000 description 7
- 229920002385 Sodium hyaluronate Polymers 0.000 description 6
- 239000013566 allergen Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 229940100601 interleukin-6 Drugs 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 229940010747 sodium hyaluronate Drugs 0.000 description 6
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 208000026935 allergic disease Diseases 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 229940015975 1,2-hexanediol Drugs 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 4
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- 229960000458 allantoin Drugs 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- 229960003237 betaine Drugs 0.000 description 4
- 229960001631 carbomer Drugs 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 3
- 230000003828 downregulation Effects 0.000 description 3
- 210000003630 histaminocyte Anatomy 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000003651 basophil Anatomy 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000005808 skin problem Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940029329 intrinsic factor Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- -1 pollen Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000021259 spicy food Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 235000014101 wine Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Abstract
The invention relates to an anti-inflammatory and soothing composition and application thereof in cosmetics, wherein the anti-inflammatory and soothing composition consists of a peony root extract and palmitoyl tripeptide-8. The radix Paeoniae extract and palmitoyl tripeptide-8 have anti-inflammatory effect, and the anti-inflammatory and soothing composition combines radix Paeoniae extract and palmitoyl tripeptide-8. The anti-inflammatory and soothing composition can simulate the anti-inflammatory activity of alpha-MSH, and can remarkably inhibit the generation of proinflammatory factors IL-1 alpha and IL-6 after being combined with a receptor MC1-R, so that the effect that 1+1 is greater than 2 is achieved, the aim of preventing and treating inflammation is fulfilled, and the anti-inflammatory and soothing effects are achieved.
Description
Technical Field
The invention relates to the field of cosmetics, in particular to an anti-inflammatory and soothing composition and application thereof in cosmetics.
Background
Along with atmospheric pollution, the radio wave radiation is continuously enhanced, the living environment of skin is more and more severe, various skin problems are continuously caused, and more than 90% of women are troubled by the skin problems every year. Global consumer surveys show that 60% of the consumers worldwide claim themselves as being sensitive to skin, and in fact, epidemiological surveys issued by the World Allergy Organization (WAO) show that 12 hundred million people are in 30 countries, with 2.5 hundred million people suffering from allergic diseases.
Allergy is an allergic reaction of the body, is an abnormal reaction of a human body to normal substances (allergens), and can occur when the allergens contact with allergic constitution, namely hundreds of kinds of allergens such as pollen, dust, foreign proteins, chemical substances, ultraviolet rays and the like. The pathogenesis of skin allergy comprises internal factors and external factors: the intrinsic factor is the inherent allergic constitution, which plays a leading role in the onset of skin allergy. Early and complete desensitization is critical to the treatment of skin allergies and prevention of recurrence. Extrinsic factors are also numerous. Including dietary, inhalant, climate, exposure to allergic factors, and the like. The seafood, protein, spicy food, wine, inhaled pollen, dust mites, cold weather, chemical contact, soap, detergent and the like are the most common causes of skin allergy, in the generation process of anaphylactic reaction, an allergic medium plays a direct role, an allergen is an external cause of allergic diseases, the immunity of an organism is low, and the oxidative damage of a large number of free radicals to mast cells and basophils is an internal cause of anaphylactic generation. Generally, when an "allergen" enters the body for the first time, mast cells or basophils bind to produce an allergic factor, but do not produce immediate allergy, and some of this property will last for 2-3 days, some months. When the organism receives the allergen for the second time, the mast cells can be deformed to generate allergic factors, and a series of allergic phenomena are generated.
At present, cosmetics using chemicals as main raw materials have failed to satisfy the demands of people for natural cosmetics with little side effects. The research mainly based on the plant and traditional Chinese medicine extracts becomes a research hotspot. The radix paeoniae extract is an extract product of Chinese herbal medicine radix paeoniae, has various active ingredients such as paeoniflorin, tea polyphenol, catechin and the like, and is an ideal raw material.
Disclosure of Invention
Based on this, there is a need for an anti-inflammatory and soothing composition containing an extract of paeonia lactiflora pall which can act as an anti-inflammatory and soothing composition.
In addition, there is a need to provide a cosmetic use of the above anti-inflammatory soothing composition.
An anti-inflammatory and soothing composition consisting of an extract of paeonia lactiflora pall and palmitoyl tripeptide-8.
The use of the above anti-inflammatory soothing composition in cosmetics.
An anti-inflammatory and soothing cosmetic composition comprises radix Paeoniae extract, palmitoyl tripeptide-8, additive and water.
The paeonia lactiflora root extract and the palmitoyl tripeptide-8 both have anti-inflammatory effects, the anti-inflammatory and soothing composition combines the paeonia lactiflora root extract and the palmitoyl tripeptide-8, and the anti-inflammatory and soothing composition can simulate the anti-inflammatory activity of alpha-MSH, and can remarkably inhibit the production of proinflammatory factors IL-1 alpha (Interleukin-1 alpha ) and IL-6 (Interleukin-6, Interleukin-6) after being combined with a receptor MC1-R, so that the effect of 1+1 & gt 2 is achieved, the purpose of preventing and treating inflammation is achieved, and the anti-inflammatory and soothing effects are achieved.
Detailed Description
In order that the invention may be more fully understood, reference will now be made to the following description taken in conjunction with the accompanying drawings. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention.
The application discloses an anti-inflammatory and soothing composition which is composed of a peony root extract and palmitoyl tripeptide-8.
The paeonia lactiflora root extract and the palmitoyl tripeptide-8 both have anti-inflammatory effects, the anti-inflammatory and soothing composition combines the paeonia lactiflora root extract and the palmitoyl tripeptide-8, and the anti-inflammatory and soothing composition can simulate the anti-inflammatory activity of alpha-MSH, and can remarkably inhibit the production of proinflammatory factors IL-1 alpha (Interleukin-1 alpha ) and IL-6 (Interleukin-6, Interleukin-6) after being combined with a receptor MC1-R, so that the effect of 1+1 & gt 2 is achieved, the purpose of preventing and treating inflammation is achieved, and the anti-inflammatory and soothing effects are achieved.
Specifically, the anti-inflammatory and soothing composition comprises the following components in parts by weight: 0.2 to 2 parts of peony root extract and 1 to 10 parts of palmitoyl tripeptide-8.
In a specific example, the anti-inflammatory and soothing composition comprises 0.4 parts, 0.6 parts, 0.8 parts, 1 part, 1.2 parts, 1.4 parts, 1.6 parts or 1.8 parts of the paeonia lactiflora root extract, and 1 part, 2 parts, 3 parts, 4 parts, 5 parts, 6 parts, 7 parts, 8 parts, 9 parts or 10 parts of palmitoyl tripeptide-8.
Preferably, when the anti-inflammatory and soothing composition is used, the mass percentage concentration of the peony root extract is 0.2-2%, and the mass percentage concentration of the palmitoyl tripeptide-8 is 1-10%.
Such anti-inflammatory soothing compositions can be applied in various fields, in particular, they can be applied in cosmetics.
According to the regulations of the regulations on the supervision and control of cosmetics and hygiene, cosmetics refer to "daily chemical industry products for cleaning, removing bad smell, caring skin, beautifying and decorating by spreading any part (skin, hair, nails, lips, etc.) on the surface of human body by smearing, spraying or other similar methods".
Therefore, skin care products also belong to cosmetics.
Specifically, the cosmetic may be a facial mask liquid, skin lotion, essence, lotion, cream or makeup.
The application also discloses an anti-inflammatory and soothing cosmetic which is composed of a peony root extract, palmitoyl tripeptide-8, an additive and water.
The paeonia lactiflora root extract and the palmitoyl tripeptide-8 both have anti-inflammatory effects, the anti-inflammatory and soothing cosmetic combines the paeonia lactiflora root extract and the palmitoyl tripeptide-8, and the anti-inflammatory and soothing composition can simulate the anti-inflammatory activity of alpha-MSH, and can remarkably inhibit the production of proinflammatory factors IL-1 alpha (Interleukin-1 alpha ) and IL-6 (Interleukin-6, Interleukin-6) after being combined with a receptor MC1-R, so that the effect of 1+1 & gt 2 is achieved, the purpose of preventing and treating inflammation is achieved, and the anti-inflammatory and soothing effects are achieved.
According to the mass parts, each hundred parts of the anti-inflammatory and soothing cosmetic comprises the following components: 0.2 to 2 parts of peony root extract, 1 to 10 parts of palmitoyl tripeptide-8, additive and the balance of water.
In a specific example, the anti-inflammatory soothing cosmetic composition comprises 0.4 part, 0.6 part, 0.8 part, 1 part, 1.2 parts, 1.4 parts, 1.6 parts or 1.8 parts of the paeonia lactiflora root extract, and 1 part, 2 parts, 3 parts, 4 parts, 5 parts, 6 parts, 7 parts, 8 parts, 9 parts or 10 parts of palmitoyl tripeptide-8.
The peony root extract is usually an alcohol extraction product.
In this embodiment, the paeonia radix extract is a paeonia radix extract. In other embodiments, other peony root extracts may be selected, for example, white peony root extract.
The additives are generally selected according to the actual product and determined in parts by mass.
The additive is a plurality of raw materials required by the production of cosmetics. Specifically, the additive may be at least one selected from the group consisting of a moisturizer, an oil, an antioxidant, a preservative, a sunscreen, a pigment, an adhesive and a perfume.
Taking the essence as an example of the anti-inflammatory and soothing cosmetic, the mass part of the additive can be 9.47 parts. At this time, the 9.47 parts of additives may be 5 parts of butylene glycol, 2 parts of propylene glycol, 0.05 parts of carbomer, 0.1 parts of sodium hyaluronate, 1 part of betaine, 0.2 parts of allantoin, 0.02 parts of disodium EDTA, 0.1 parts of arginine, 0.5 parts of 1, 2-hexanediol, and 0.5 parts of p-hydroxyacetophenone.
When the anti-inflammatory and soothing cosmetic is essence, the preparation method comprises the following steps:
weighing various raw materials according to the mass parts, stirring and dispersing carbomer, adding pre-dissolved propylene glycol and sodium hyaluronate, adding water, butanediol, sodium hyaluronate, betaine, allantoin and EDTA disodium while stirring, heating to 80 ℃, stirring until the materials are uniformly dissolved, and keeping the temperature for 20 min;
cooling the mixed solution to about 45 ℃, sequentially adding the peony root extract, palmitoyl tripeptide-8, arginine, 1, 2-hexanediol and p-hydroxyacetophenone, and uniformly stirring;
cooling the mixed solution to below 38 deg.C to obtain essence.
DETAILED DESCRIPTION OF EMBODIMENT (S) OF INVENTION
Example 1: the anti-inflammatory and soothing essence is prepared from 100 parts of total mass part, 0.5 part of radix paeoniae rubra extract, 1 part of palmitoyl tripeptide-8, 5 parts of butanediol, 2 parts of propylene glycol, 0.05 part of carbomer, 0.1 part of sodium hyaluronate, 1 part of betaine, 0.2 part of allantoin, 0.02 part of disodium EDTA, 0.1 part of arginine, 0.5 part of 1, 2-hexanediol, 0.5 part of p-hydroxyacetophenone and the balance of water.
Weighing the raw materials according to the mass parts, stirring and dispersing carbomer, adding pre-dissolved propylene glycol and sodium hyaluronate, adding water, butanediol, sodium hyaluronate, betaine, allantoin and EDTA disodium while stirring, heating to 80 ℃, stirring until the materials are uniformly dissolved, and keeping the temperature for 20 min;
cooling the mixed solution to about 45 ℃, sequentially adding the peony root extract, palmitoyl tripeptide-8, arginine, 1, 2-hexanediol and p-hydroxyacetophenone, and uniformly stirring;
and cooling the mixed solution to below 38 ℃ to obtain the anti-inflammatory and soothing essence.
Example 2: preparation of anti-inflammatory and soothing essence
Example 2 is different from example 1 only in that the part of the extract of red peony is 1.2 parts, the part of palmitoyl tripeptide-8 is 6 parts, and the others are not different.
An anti-inflammatory soothing essence was prepared in the same manner as in example 1.
Example 3: preparation of anti-inflammatory and soothing essence
Example 3 is different from example 1 only in that the part of the extract of red peony is 2 parts, the part of palmitoyl tripeptide-8 is 10 parts, and the others are not different.
An anti-inflammatory soothing essence was prepared in the same manner as in example 1.
Example 4: HaCat cell-based anti-inflammatory efficacy assays (for IL-1. alpha. and IL-6)
Raw materials and drugs
HaCat cells, MEM culture solution (Gibco), PBS (doctor de), MTT (Sigma), DMSO (Sigma), LPS (Sigma), ELISA kit (CUSABIO), radix Paeoniae Rubra extract (liquid, Shanghai Prinsepiae Xiye Ltd.), and palmitoyl tripeptide-8 (Shanghai Prinsepiae Xiye Ltd.).
Device
CO2Incubator (Thermo), clean bench (Sujing Antai), inverted microscope (Olympus), micro-oscillator (Linbel), enzyme labeling instrument (BioTek), and incubator (Tester).
Determining the efficacy detection concentration based on cytotoxicity detection, establishing an inflammation model by taking LPS as a stimulant and based on HaCat cells, and performing experiments on the peony root extracts with different concentrations. And collecting the acted HaCat cells, and detecting by adopting an enzyme-linked immunosorbent assay (ELISA).
The specific operation steps are as follows:
1) cell inoculation and preparation: the cells were packed at a density of 2.0X 105～3.0×105Inoculating the strain/mL/hole into a 12-hole plate, and returning to an incubator for culturing for 18-24 h;
2) administration: preparing test substances with different concentrations according to the table 1;
table 1: anti-inflammatory efficacy testing experimental design
3) Collecting cell culture solution: after the culture was completed, the cell culture solution was collected in a 1.5mL Eppendorf tube, centrifuged to take the supernatant, and frozen in a freezer at-80 ℃ for ELISA detection.
4) And (3) data analysis: the data of the test results are expressed as mean ± standard deviation, and the data are analyzed by SPSS, and if p is less than 0.05, the difference is considered to be statistically significant.
Among them, the ELISA assay for IL-1. alpha. is shown in Table 2, and the ELISA assay for IL-6 is shown in Table 3.
Table 2: IL-1 alpha content detection results
Compared with a model group, the significance labeling method comprises the following steps: "+" indicates significant difference, p < 0.05; "n.s" indicates no statistical difference, p > 0.05.
As can be seen from table 2, control group 1, control group 2, sample group 1, sample group 2 and sample group 3 all function to down-regulate the IL-1 α factor, and the down-regulation effect of sample group 1, sample group 2 and sample group 3 is apparently due to control group 1 and control group 2. Thus, the combined use of the extract of radix paeoniae rubra and palmitoyl tripeptide-8 can achieve the effect of 1+1 > 2 in the aspect of down-regulating IL-1 alpha factor.
Furthermore, it can be seen from table 2 that sample set 2 has significant advantages over sample sets 1 and 3.
Table 3: IL-6 content assay results
Compared with a model group, the significance labeling method comprises the following steps: "+" indicates significant difference, p < 0.05; "n.s" indicates no statistical difference, p > 0.05.
As can be seen from table 3, control group 1, control group 2, sample group 1, sample group 2 and sample group 3 all were able to function to down-regulate the IL-6 factor, and the down-regulation effect of sample group 1, sample group 2 and sample group 3 was apparently due to control group 1 and control group 2. Thus, the combined use of the extract of radix paeoniae rubra and palmitoyl tripeptide-8 can achieve the effect of 1+1 > 2 in the aspect of down-regulation of IL-6 factor.
Furthermore, it can be seen from table 2 that sample set 2 has significant advantages over sample sets 1 and 3.
The above-mentioned embodiments only express several embodiments of the present invention, and the description thereof is more specific and detailed, but not construed as limiting the claims. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention. Therefore, the protection scope of the present patent shall be subject to the appended claims.
Claims (10)
1. An anti-inflammatory and soothing composition comprising an extract of paeonia lactiflora and palmitoyl tripeptide-8.
2. An anti-inflammatory soothing composition according to claim 1, wherein the anti-inflammatory soothing composition consists of the following components in parts by weight: 0.2 to 2 parts of peony root extract and 1 to 10 parts of palmitoyl tripeptide-8.
3. An anti-inflammatory and soothing composition as claimed in claim 2, wherein the portion by mass of the paeonia lactiflora extract is 0.4, 0.6, 0.8, 1, 1.2, 1.4, 1.6 or 1.8;
the mass portion of the palmitoyl tripeptide-8 is 1 portion, 2 portions, 3 portions, 4 portions, 5 portions, 6 portions, 7 portions, 8 portions, 9 portions or 10 portions.
4. An anti-inflammatory and soothing composition as claimed in any one of claims 1 to 3, wherein the concentration of the paeonia lactiflora extract is 0.2-2% by weight and the concentration of the palmitoyl tripeptide-8 is 1-10% by weight when the composition is used.
5. An anti-inflammatory soothing composition according to any of claims 1 to 4 for use in cosmetics.
6. The use according to claim 5, wherein the cosmetic product is a facial mask solution, a skin lotion, a serum, an emulsion, a cream or a make-up.
7. An anti-inflammatory soothing cosmetic, which is characterized by comprising a peony root extract, palmitoyl tripeptide-8, an additive and water.
8. An anti-inflammatory soothing cosmetic as claimed in claim 7, wherein the anti-inflammatory soothing cosmetic consists of the following components per hundred parts by weight: 0.2 to 2 parts of peony root extract, 1 to 10 parts of palmitoyl tripeptide-8, additive and the balance of water.
9. An anti-inflammatory and soothing cosmetic as claimed in claim 8, wherein the portion of the paeonia lactiflora extract is 0.4, 0.6, 0.8, 1, 1.2, 1.4, 1.6 or 1.8 parts by weight;
the mass portion of the palmitoyl tripeptide-8 is 1 portion, 2 portions, 3 portions, 4 portions, 5 portions, 6 portions, 7 portions, 8 portions, 9 portions or 10 portions.
10. An anti-inflammatory soothing cosmetic as in claim 8 wherein the additive is selected from at least one of moisturizers, oils, antioxidants, preservatives, sunscreens, pigments, adhesives and fragrances.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010207882.4A CN112842954A (en) | 2020-03-23 | 2020-03-23 | Anti-inflammatory and soothing composition and application thereof in cosmetics |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010207882.4A CN112842954A (en) | 2020-03-23 | 2020-03-23 | Anti-inflammatory and soothing composition and application thereof in cosmetics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112842954A true CN112842954A (en) | 2021-05-28 |
Family
ID=75996089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010207882.4A Pending CN112842954A (en) | 2020-03-23 | 2020-03-23 | Anti-inflammatory and soothing composition and application thereof in cosmetics |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112842954A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114796070A (en) * | 2022-04-08 | 2022-07-29 | 广州市华远生物科技有限公司 | Anti-inflammatory and antiallergic wound healing flower composition with repairing function and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109010115A (en) * | 2018-10-19 | 2018-12-18 | 中山爱护日用品有限公司 | A kind of Shu Min creams with anti-inflammatory efficacy |
| CN109106664A (en) * | 2018-08-13 | 2019-01-01 | 广州皓雨投资有限公司 | Have effects that moisturizing is releived the composition of maintenance, facial mask and preparation method thereof |
| CN109674734A (en) * | 2019-01-22 | 2019-04-26 | 郑娇娇 | It is a kind of with moisturizing, maintenance, releive, the composition of Antiageing effect and its application |
| CN110200830A (en) * | 2019-05-23 | 2019-09-06 | 广州科斯曼生物科技有限公司 | A kind of anti-inflammatory Shu Min remediation composition and its preparation method and application |
-
2020
- 2020-03-23 CN CN202010207882.4A patent/CN112842954A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109106664A (en) * | 2018-08-13 | 2019-01-01 | 广州皓雨投资有限公司 | Have effects that moisturizing is releived the composition of maintenance, facial mask and preparation method thereof |
| CN109010115A (en) * | 2018-10-19 | 2018-12-18 | 中山爱护日用品有限公司 | A kind of Shu Min creams with anti-inflammatory efficacy |
| CN109674734A (en) * | 2019-01-22 | 2019-04-26 | 郑娇娇 | It is a kind of with moisturizing, maintenance, releive, the composition of Antiageing effect and its application |
| CN110200830A (en) * | 2019-05-23 | 2019-09-06 | 广州科斯曼生物科技有限公司 | A kind of anti-inflammatory Shu Min remediation composition and its preparation method and application |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114796070A (en) * | 2022-04-08 | 2022-07-29 | 广州市华远生物科技有限公司 | Anti-inflammatory and antiallergic wound healing flower composition with repairing function and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103070810B (en) | Anti-skin-aging composition | |
| CN102026616B (en) | Substances that increase the activation threshold of immune cells | |
| CN108294992A (en) | A kind of acne-removing composition | |
| CN113041190B (en) | Antioxidant composition, preparation method and application | |
| KR20190056815A (en) | A composition for improving skin diseases containing extracts of abeliophyllum distichum and extract thereof having skin reproduction effect | |
| KR20120048864A (en) | A method for preparing the preventive and therapeutic compositions for atopic dermatitis | |
| KR101860109B1 (en) | Skin external composition containing floral ginsenoside | |
| KR20180082177A (en) | Cosmetic composition comprising saccharomyces ferment filtrate, asparagus officinalis stem extract and tussilago farfara flower extract | |
| CN112842954A (en) | Anti-inflammatory and soothing composition and application thereof in cosmetics | |
| TWI729618B (en) | Use of phalaenopsis plant extract for anti-glycation and improving skin appearance | |
| KR19990086516A (en) | Anti-aging cosmetic composition containing ginseng extract | |
| KR102563369B1 (en) | Moringa peregrina seed extract rich in 2,5-diformylfuran, process for its preparation and its use in cosmetic compositions | |
| JP3496967B2 (en) | Antiplasmin agent | |
| KR101477552B1 (en) | A pharmaceutical composition for the treatment of atopic dermatitis and method of production thereof | |
| CN117396180A (en) | Cosmetic composition simulating human placenta | |
| KR100532633B1 (en) | Cosmetic composition having anti-inflammatory, skin-protecting, skin-elastic effects which comprise mixed plants extract | |
| CN115054532A (en) | Compound small-molecule active peptide moisturizing secondary polishing essence | |
| KR102034436B1 (en) | Composition For Treating And Preventing Atopic Dermatitis Comprising Ternstroemia kwangtungensis Merr. Extracts | |
| KR20110063912A (en) | A topical composition comprising the extract of platycodi radix, bupleuri radix and ginseng radix and the purified fractions therefrom inhibiting skin aging and wrinkle formation | |
| CN108883142B (en) | Bioactive compositions from ginseng plant (PANAX SPP.) and methods of making and using same | |
| CN111096914A (en) | Hemp leaf mask for cleaning and balancing face and preparation method thereof | |
| KR101398392B1 (en) | cosmetic compositions containing extract of Viburnum dilatatum Thunb used for antiwrinkle | |
| CN115337216B (en) | Skin care product combination with relieving effect and preparation method thereof | |
| TWI788019B (en) | Use of chamaemelum nobile extract for manufacturing skincare composition | |
| CN115969759B (en) | Photoprotective plant extract compositions and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210528 |